Drugs / LC002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00270205 | Jan 2006 → Sep 2010 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LC002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00270205 ↗ |
| Modality | Vaccine | “LC002 is an experimental therapeutic vaccine designed to boost the immune response of people infected with HIV.” NCT00270205 ↗ |
| Route | Subcutaneous | “0.1 mg DNA/participant, 0.8 ml total administered subcutaneously” NCT00270205 ↗ |